ReviewDigestive diseases and sciences2019
Update on the Diagnosis and Management of Gastric Intestinal Metaplasia in the USA.
Review in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Autophagy: Mechanisms and therapeutic perspectives in intestinal metaplasia (Review).Molecular medicine reports · 2026Review
- The role of cuproptosis in gastric cancer.Frontiers in immunology · 2024Review
- The Difference of Endoscopic and Histologic Improvements of Atrophic Gastritis and Intestinal Metaplasia After Helicobacter pylori Eradication.Digestive diseases and sciences · 2022Article
- Comparison between the Linked Color and White Light Imaging Combined Score in the Evaluation of High-Risk Population of Gastric Cancer.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- Article
- Histopathological classification and follow-up analysis of chronic atrophic gastritis.World journal of clinical cases · 2021Article
- The Transition from Gastric Intestinal Metaplasia to Gastric Cancer InvolvesInternational journal of molecular sciences · 2021Article
- Factors associated with the progression of gastric intestinal metaplasia: a multicenter, prospective cohort study.Endoscopy international open · 2021Article
- CytokineInternational journal of medical sciences · 2021Observational
- Histomorphological Characteristics and Pathological Types of Hyperproliferation of Gastric Surface Epithelial Cells.Gastroenterology research and practice · 2021Article
- Diagnosis: gastric intestinal metaplasia - what to do next?Current opinion in gastroenterology · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric intestinal metaplasia (GIM) is a premalignant condition that can lead to intestinal-type gastric adenocarcinoma. It is characterized by a change in the gastric mucosa to a small-intestinal phenotype. Infection with Helicobacter pylori is the most common factor associated with GIM. Although GIM is typically a histologic diagnosis, various techniques have been developed to enable the endoscopic identification of GIM. There are presently no widely accepted guidelines on screening and surveillance strategies in patients with GIM in the USA. The aim of this review is to provide an update regarding the problem, diagnosis, and management of GIM in the USA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.